Jan 9 (Reuters) - Abivax SA ABVX.PA:
ABIVAX ACHIEVES KEY MILESTONE IN PHASE 3 ABTECT TRIAL ENROLLMENT
TOP-LINE RESULTS FOR 8-WEEK INDUCTION TRIAL EXPECTED IN Q3 2025
ENROLLMENT COMPLETION EXPECTED IN Q2 2025
PHASE 3 ABTECT TRIAL REACHES 82% OF TARGET ENROLLMENT
Source text: nGNXb5Lpc9
Further company coverage: ABVX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))